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A B S T R A C T
Parkinson’s disease (PD) - the second most common neurodegenerative disorder - is a multifactorial disease, the causes of which should be sought in complex and
detrimental interactions between genetic and environmental factors. Multiple lines of evidence, however, identify mitochondrial dysfunction, oxidative stress, and
iron accumulation as central pathogenic mechanisms. These factors are closely intertwined because mitochondria are a major source of pro-oxidant species and are
the major intracellular recipients of iron. How iron is transported to mitochondria, however, is largely unknown. Some studies suggest that trafficking through
endocytosis may participate to mitochondrial iron delivery with a “kiss and run” mechanism. Intracellular transferrin levels increase in PD, possibly as a consequence
of oxidation of iron-containing prosthetic groups in mitochondria. It is therefore conceivable that transferrin endocytic trafficking can contribute to noxious iron
accumulation. This short review will summarize these findings and discuss their relevance for a better understanding of PD pathogenesis.
1. Introduction
Parkinson’s disease (PD) is the second most common neurodegen-
erative disorder after Alzheimer’s and is characterized by a rather se-
lective degeneration of dopaminergic neurons in the substantia nigra
pars compacta (SNpc). The vast majority of PD cases (> 90%) is
sporadic and the causes are likely rooted in the complex interaction
between genetic predisposing factor and environmental stimuli.
Multiple lines of evidence, however, indicate that oxidative stress and
defects in mitochondrial function - and decreased complex I activity in
particular - are central to PD pathogenesis (Anandhan et al., 2017).
Dopaminergic neurons are characterized by a particularly oxidized in-
tracellular environment also in normal, non-pathological conditions, as
indicated by an increased ratio between oxidized and reduced cysteines
in glutathione and proteins when compared to neurons in other ana-
tomical regions (Guzman et al., 2010; Mastroberardino et al., 2009,
2008). Consistently, they are particularly vulnerable to toxins per-
turbing mitochondrial function and leading to increased production of
pro-oxidant species, which are typically used to model PD (Martinez
and Greenamyre, 2012). Additionally, the parkinsonian SNpc is char-
acterized by markedly increased levels of iron (Berg and Hochstrasser,
2006).
2. Iron
Iron is the most represented transition metal in the cell and is
essential for life. Iron can reversibly transition between different oxi-
dation states, most commonly ferrous and ferric iron, i.e. Fe2+ and
Fe3+ respectively. Because ferric iron is scarcely soluble and tends to
precipitate, bioavailable iron is principally in the form of Fe2+. Iron is a
first raw transition element with incompletely filled d orbitals and can
therefore easily participate to oxido-reductive (redox) reactions. This
property makes this metal particularly suitable as a cofactor in nu-
merous enzymatic reactions, including that catalyzed by tyrosine hy-
droxylase in the initial and rate limiting step of dopamine synthesis
(Nagatsu et al., 2018). The very same redox unique properties, how-
ever, render iron also potentially harmful. For instance, ferrous iron
very rapidly reacts with hydrogen peroxide to ultimately generate the
highly toxic hydroxyl radical (Fenton reaction). In the organism, iron is
therefore typically complexed with proteins that serve for its acquisi-
tion, transport (e.g. transferrin), or storage means (e.g. ferritin). Details
on iron metabolism are summarized in several excellent reviews, e.g.
(Chen and Paw, 2012; Pantopoulos et al., 2012). However, for the
purposes of this article, it is important to clarify that the vast majority
of iron is imported in the cell in a transferrin (Tf)-bound form, via an
endocytic mechanism that involves transferrin receptors (TfRs). Thus
far, two TfRs isoforms have been identified, TfR1 and TfR2. These
proteins are largely non-redundant, performing different functions,
because TfR2 cannot replace TfR1 in cells in which the latter has been
silenced (Trinder and Baker, 2003). Consistently, experimental evi-
dence highlighted several differences between TfR1 and TfR2. TfR2 has
lower affinity (approximately 30-fold less) for iron loaded transferrin
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(i.e. holotransferrin) than TfR1 (Kawabata et al., 2000; West et al.,
2000). While TfR1 is largely regulated by intracellular iron levels via
the iron responsive element-iron regulatory protein (IRE-IRP) me-
chanism: high iron concentration exposes an instability element in the
mRNA 3′ UTR in the mRNA, therefore promoting degradation. Con-
versely, TfR2 lacks the iron responsive 3′ UTR element and therefore
does not directly respond to intracellular iron concentration (Kawabata
et al., 2001). Additionally, unlike TfR1, TfR2 cannot bind the regulatory
protein HFE (West et al., 2000), which is mutated in patients with
hereditary hemochromatosis and negatively regulates TfR1-mediated
iron uptake, at least in cell culture experimental systems (Corsi et al.,
1999; Gross et al., 1998; Roy et al., 1999). Finally, recent study indicate
that TfR2 acts in concert with the hormone hepcidin, the master iron
regulator of the body, to maintain systemic iron homeostasis (Drake
et al., 2007; Kawabata et al., 2005).
3. The endo-lysosomal system
In general terms, endocytosis refers to the process that leads to in-
ternalization of molecules and fluids from the extracellular environ-
ment through the invagination of the plasma membrane and subsequent
fission of the latter in vesicles, or endosomes. The endocytic process is
responsible for transporting biological molecules – or cargos – to their
final subcellular compartment. Cargos can then be either recycled via
shuttling to the plasma membrane, or degraded in the lysosomal com-
partment. Consistently with these general functions, the endo-lyso-
somal compartment has been originally classified in early endosomes
(EE), recycling endosomes (RE), late endosomes (LE), and lysosomes
(L), which also display different ultrastructural features (see (Huotari
and Helenius, 2011) for review). Quantitative estimates of endosomal
activity described in early studies clearly illustrate the proportions - and
thus the biological importance - of this process. Cargos internalization is
in fact very rapid – it requires only in a few minutes - and recycling
involves a very large fraction of the plasma membrane. In contrast,
transport for degradation to lysosomes represents a relatively smaller
proportion of internalized membranes (Besterman and Low, 1983;
Steinman et al., 1983). Current knowledge of the mechanisms re-
sponsible for transporting a cargo to degradation is reasonably ad-
vanced (Henne et al., 2013) and has been excellently reviewed, also in
very recent articles, approaching the problem from the perspective of
mitochondria PD (e.g. (Plotegher and Duchen, 2017)). Conversely, our
understanding of the recycling branch of the endosomal system highly
rudimentary (Hsu et al., 2012).
Overall, the endo-lysosomal compartment is a highly active cellular
component governing membrane trafficking as well as proteostasis,
therefore participating to the regulation of a multitude of biological
pathways. Consistently, the endo-lysosomal machinery is essential for
life and its dysfunction is associated with pathology or even lethality.
4. Molecular mechanisms of endocytosis
The endosomal machinery must recognize a cargo and its load, for
instance transferrin and its receptor, extract these proteins from the
plasma membrane via formation of a vesicle, direct the latter to its
subcellular destination, and possibly re-shuttle these components to the
plasma membrane for recycling. Endosomal protein sorting and traf-
ficking is regulated by the heteropentameric complex retromer, which
is composed by two distinct modules, one of which ensures recognition
of the cargo complex, while the other is responsible for tubulation i.e.
the formation of tubules that operate cargo transport to its destination.
The recognition complex is a heterotrimer composed by the proteins
VPS26, VPS29, and VPS35. The latter constitutes the backbone used by
the other two proteins to bind and form the complex (Burd and Cullen,
2014). The tubulation complex is a heterodimer composed of a subset of
Sorting Nexins (Snxs) - Snx1, Snx2, Snx5, and Snx6 - which can be
present in variable combinations and are crucial for correct trafficking
organization. In addition, other 29 different SNXs have been identified
in mammals (Cullen, 2008; Cullen and Korswagen, 2011). The precise
role of these proteins has not been fully characterized yet; nonetheless,
such abundance points to specialized functions that may regulate en-
docytosis in a cargo and/or tissue specific fashion. Mechanistically, Snx
bind via their phox-homology (PX) domain to the phospholipids
phosphatidylinositol-3-phosphate (PtdIns3P) and phosphatidylinositol-
3,5-bisphosphate (PtdIns3,5P2), which are enriched in early and late
endosomes (Cullen and Korswagen, 2011).
5. Mitochondria
Generation of ATP via oxidative phosphorylation (OXPHOS) - i.e.
electron transport between respiratory complexes to generate a proton
gradient across the inner mitochondrial membrane that will be used as
thermodynamic driving force for the ATP synthase - is the principal
function of mitochondria (Nicholls and Ferguson, 2013). Importantly,
other functional aspects of mitochondria, for instance calcium buffering
and production of reactive oxygen species to operate redox signaling,
also depend on electron transport and proton gradient maintenance
(Murphy, 2009).
Iron is particularly important for mitochondrial biology. Electron
transport, in fact, is possible because of iron-containing prosthetic
groups such as heme and iron-sulfur clusters (ISCs), which serve dif-
ferent purposes: from redox reactions to oxygen transport, to structural
functions (Braymer and Lill, 2017). Of note, the biosynthesis of heme
occurs exclusively in mitochondria and ISCs are prevalently assembled
in these organelles (Braymer and Lill, 2017). Because of these particular
features, mitochondria are the major recipient of iron in the cell.
How iron enters mitochondria, however, is highly debated. Given
free iron propensity to engage in potentially detrimental redox reac-
tions with products of mitochondrial metabolism (e.g. O2 or H2O2), it is
highly unlikely that iron transfer occurs independently from chaperone
proteins or mechanisms. Two proteins functioning as uniporter in-
volved in mitochondrial iron uptake – mitoferrin 1 and mitoferrin-2 -
have been identified thus far (Paradkar et al., 2009; Shaw et al., 2006)
and recent evidence indicates that mitoferrin 1 functions as uniporter
transporting unchelated ferrous iron (Christenson et al., 2018). There is
large consensus, however, that mitochondrial iron import cannot solely
rely on these protein; yet, our understanding of alternative mitochon-
drial iron import mechanisms is highly rudimentary.
6. Endocytosis in the brain
Neurons are characterized by extremely arborized processes that
can reach considerable length and therefore display unique cytological
complexity. Additionally, neurons are post-mitotic cells and must sur-
vive for the entire lifespan of an organism, which in humans reaches
almost one hundred years. Neurons therefore require particularly ro-
bust intracellular trafficking machinery and quality control mechan-
isms, which are reflected in the distinctive cyto-architecture of their
endo-lysosomal system. The latter is in fact highly compartmentalized,
with different classes of endo- lysosomes located in different cytological
domains. For instance, while late endosomes are rather homogeneously
distributed, lysosomes with high degradative capacity are typically lo-
cated in the neuron soma or in proximal neurites and dendrites. A the
molecular level, expression of degradative lysosomal markers such as
hydrolases manifest progressively as the endosomes are transported
toward the soma (Winckler et al., 2018).
During development, migration of neurons is essential for proper
function of the adult brain and, when defective, is associated to con-
ditions such as epilepsy and mental retardation. The process is also
mediated by membrane receptors and by their appropriate endocytic
intracellular trafficking (Yap and Winckler, 2015). Consistently, dele-
tion of essential components of the endocytic machinery – for instance
retromer - results in embryonic lethality (Schwarz et al., 2002).
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Adequate endocytosis is also critical for the adult brain, as evi-
denced by the effects of mutation in genes on the endocytic pathway.
Studies based on exome sequencing, in fact, identified genetic asso-
ciation between the VPS35(p.D620 N) mutation and PD (Vilarino-Guell
et al., 2011; Zimprich et al., 2011). Other follow up studies identified
additional non-synonymous mutations (reviewed in (McMillan et al.,
2017). Thus far, available evidence indicates that none of the mutations
that have been analyzed at mechanistic level drastically alters the ret-
romer complex and result only in mild trafficking defects (Follett et al.,
2016; McMillan et al., 2016, 2017). Moreover, post-mortem brains of
idiopathic PD patients fail to exhibit alterations in VPS35 subcellular
distribution, despite viral-mediated overexpression of VPS35(p.D620 N)
induces dopaminergic degeneration in laboratory rodent models (Tsika
et al., 2014). Further complexity arises from a study also identified
healthy carriers, therefore suggesting incomplete penetrance of this
mutation (Sharma et al., 2012).
Although the lack of consensus on the mechanisms explaining the
role of VPS35 in PD pathogenesis, multiple lines of evidence sub-
stantiate the relevance of retromer in PD. For instance, dopaminergic
signaling through the dopamine D1 receptor (D1R) – and thus through
the direct striatonigral pathway - is contributed by rapid D1R en-
docytosis (Kotowski et al., 2011). Moreover, several independent re-
ports indicate biological interaction between the kinase LRRK2 – the
principal genetic risk factor for PD - and VPS35. For instance, in animal
models, wild-type VPS35 can rescue Lrrk2 associated defects and
overexpression of the mutated VPS35 form alters the normal Lrrk2 as-
sociated phosphoproteome pattern (Fujimoto et al., 2018; Inoshita
et al., 2017; Linhart et al., 2014; MacLeod et al., 2013; Mir et al., 2018).
The latter evidence further corroborates the nexus between PD, en-
docytosis, and LRRK2, because its phosphorylation targets are abun-
dantly represented by a subset of Rab GTPases (Steger et al., 2016),
which are fundamental players in the endocytic process (Pfeffer, 2017).
A further potential nexus with PD emerges from data showing that
overexpression of wild-type VPS 35 is protective against the PD-related
mitochondrial toxins MPTP and rotenone (Bi et al., 2013; Linhart et al.,
2014). Despite the latter evidence highlights a connection between
endocytosis and mitochondria, endocytic trafficking toward these or-
ganelles is still poorly understood.
It has been shown that VPS35 can influence mitochondrial dynamics
– possibly in a detrimental way in the case of PD associated mutations-
even though evidence is not conclusive given that two different studies
reported opposite effects, i.e. favoring mitochondrial fission (Wang
et al., 2016) or fusion (Tang et al., 2015). An unbiased screen, however,
found that VPS35 localizes to mitochondria, where it can direct
endocytic trafficking (Braschi et al., 2010). These results are consistent
with previous findings from our laboratory demonstrating that Tf can
be targeted to mitochondria via TfR2, through a mechanism that can
possibly involve an active mitochondrial targeting sequence at the N-
terminal of the latter protein (Mastroberardino et al., 2009). Direct
endocytic trafficking of Tf/TfR1 to mitochondria has been initially
proposed by pioneering studies in erythroid cells (Isobe et al., 1981;
Richardson et al., 2010; Sheftel et al., 2007), via a transient “kiss and
run” mechanism. A further and more recent independent study used
super-resolution microscopy to confirm this evidence in non-erythroid
cells (Das et al., 2016). Importantly, these studies also indicate that the
Tf/TfRs endocytic pathway can deliver iron to mitochondria. It should
be emphasized, however, that the mechanisms mediating endosomal
docking onto mitochondria are unknown.
Endosomal trafficking to mitochondria may be of particular re-
levance for PD because evidence gathered in rodents, non-human pri-
mates, and patients show that pathogenesis and iron accumulation are
accompanied by increased Tf levels in dopaminergic neurons
(Mastroberardino et al., 2009). Iron uptake via the endocytic pathway
may therefore be a significant route of iron accumulation even though it
is not known yet whether PD patients carrying mutations in the en-
docytic protein VPS35 also display iron accumulation, and, if so, to
which extent (Funke et al., 2013).
Mechanistically, iron uptake may be driven by increasing oxidative
stress in DA neurons, which occurs during PD progression
(Mastroberardino et al., 2009, 2008). Oxidant species may oxidize ISCs,
for instance from [4Fe-4S]2+ to the inactive [3Fe-4S]1+, with con-
sequent decrease in the number of functional mitochondrial proteins
relying on these prosthetic groups (Gardner et al., 1995; Vasquez-Vivar
et al., 2000). Here, it should be noted that oxidation of [4Fe-4S]2+ to
inactive [3Fe-4S]1+ produces ferrous iron and hydrogen peroxide
therefore lay foundation for potentially detrimental redox cycling
(Vasquez-Vivar et al., 2000). It has also been proposed that ISCs in
proteins may act as sensors of mitochondrial iron status and chemical or
genetic depression of ISC or heme synthesis alters Tf and iron biology,
even though with counterintuitive consequences. In fact, one would
think that such depression should in principle reduce mitochondrion
iron need; it sorts, instead opposite effects, causing increased uptake of
Tf-bound iron, which culminates in mitochondrial iron overload
(Huang et al., 2009). The mechanisms driving this process are obscure,
but iron uptake despite apparent lack of necessity (i.e. without heme or
ISC biosynthesis) is generally interpreted as an attempt of the cell to
rescue the synthesis of these important molecules. Accordingly, ISC
oxidation is may be reversed in ferrous iron excess (Vasquez-Vivar
Fig. 1. Schematic summarizing the interactions between endosomes and mitochondria in healthy conditions and in PD. Endosomes may physiologically contribute to
iron import in mitochondria via a transferrin-mediated kiss-and-run mechanism (left panel). In PD, oxidation of iron-sulfur clusters may represent a stimulus to
increase iron import (right panel). Oxidative stress may prevent proper endosomes’ recycling, which can further increases intracellular iron levels. Collectively, these
phenomena trigger a vicious circle escalating oxidative stress and promoting pathogenesis.
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et al., 2000). On these premises, Tf increase observed in the rotenone
model of PD and in patients’ specimens can be interpreted as a con-
sequence of ISC oxidation – which is supported by biochemical evi-
dences in vitro and ex vivo (Flint et al., 1993; Panov et al., 2005) –
leading to increased TfR cycling rate to promote ISC synthesis. When
trafficking is mediated by TfR2, which does not contain an IRE and is
therefore not directly regulated by iron concentration, increased Tf
uptake under oxidative stress conditions may further aggravate iron
overload (Fig.1).
7. Conclusions
A role for alterations in endocytosis in PD pathogenesis is rapidly
gaining momentum. Endocytic trafficking connects critical aspects of
PD pathobiology, such as mitochondrial defects, iron mishandling, and
oxidative stress, and it might therefore constitute a tractable target for
future therapeutic interventions.
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